88 research outputs found

    Zero phase sequence voltage injection for the alternate arm converter

    Get PDF
    The Alternate Arm Converter (AAC) is a voltage source converter being developed as an alternative to the Modular Multilevel Converter (MMC) for HVDC power transmission and reactive power compensation. Each Arm of the converter contains high voltage series IGBT Director Switches and full-bridge cells, which enables the VSC to ride through AC and DC network faults. This paper describes how the AAC can be optimised by modulating the converter terminal voltages with zerophase sequence triplen harmonic components. The optimisation reduces the ratio of the number of the full-bridge cells compared to the simpler Director Switches which offers a valuable improvement in footprint and efficiency

    The Alternate Arm Converter: A New Hybrid Multilevel Converter With DC-Fault Blocking Capability

    No full text
    This paper explains the working principles, supported by simulation results, of a new converter topology intended for HVDC applications, called the alternate arm converter (AAC). It is a hybrid between the modular multilevel converter, because of the presence of H-bridge cells, and the two-level converter, in the form of director switches in each arm. This converter is able to generate a multilevel ac voltage and since its stacks of cells consist of H-bridge cells instead of half-bridge cells, they are able to generate higher ac voltage than the dc terminal voltage. This allows the AAC to operate at an optimal point, called the “sweet spot,” where the ac and dc energy flows equal. The director switches in the AAC are responsible for alternating the conduction period of each arm, leading to a significant reduction in the number of cells in the stacks. Furthermore, the AAC can keep control of the current in the phase reactor even in case of a dc-side fault and support the ac grid, through a STATCOM mode. Simulation results and loss calculations are presented in this paper in order to support the claimed features of the AAC

    GH Receptor Antagonist: Mechanism of Action and Clinical Utility

    Full text link
    This review focuses on the development of GH receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. A brief overview of acromegaly, its diagnosis and existing medical, surgical and radiotherapy options of treatment is necessary to justify the addition of yet another therapeutic modality to the already vast therapeutic armamentarium.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/47874/1/11154_2005_Article_5219.pd
    corecore